Atara Biotherapeutics, Inc.
$4.99
▼
-3.48%
2026-04-21 05:28:00
www.atarabio.com
NMS: ATRA
Explore Atara Biotherapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$42.24 M
Current Price
$4.99
52W High / Low
$19.14 / $3.92
Stock P/E
1.29
Book Value
$-5.26
Dividend Yield
—
ROCE
674.99%
ROE
-48.15%
Face Value
—
EPS
$2.57
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
14
Beta
-0.33
Debt / Equity
-0.27
Current Ratio
0.82
Quick Ratio
0.82
Forward P/E
5.74
Price / Sales
0.31
Enterprise Value
$39.92 M
EV / EBITDA
0.77
EV / Revenue
0.33
Rating
Hold
Target Price
$9.33
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Net margin remains healthy.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Maravai LifeSciences Holdings, Inc. | $3.61 | — | $928.01 M | — | -17.71% | -48.59% | $4.11 / $1.67 | $1.46 |
| 2. | Krystal Biotech, Inc. | $276.4 | 40.42 | $8.11 B | — | 13.1% | 18.91% | $298.3 / $122.8 | $41.78 |
| 3. | REGENXBIO Inc. | $9.47 | — | $488.82 M | — | -48.13% | -1.07% | $16.19 / $5.85 | $2.02 |
| 4. | Oncolytics Biotech Inc. | $1.11 | — | $163.05 M | — | -1939.57% | 11480.64% | $1.85 / $0.45 | $0 |
| 5. | ArriVent BioPharma, Inc. | $31.39 | — | $1.31 B | — | -57.79% | -58.88% | $30.72 / $16.1 | $7.24 |
| 6. | Prelude Therapeutics Incorporated | $4.51 | — | $279.73 M | — | -118.39% | -99.45% | $5.54 / $0.72 | $0.83 |
| 7. | Oragenics, Inc. | $0.71 | — | $3.19 M | — | -113.05% | -2.44% | $9.6 / $0.5 | $1.94 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 1.59 M | 3.45 M | 17.57 M | 98.15 M | 32.75 M | — |
| Operating Profit | -2.56 M | -3.57 M | 3.78 M | 38.8 M | -12.2 M | — |
| Net Profit | -3.41 M | -4.3 M | 2.39 M | 38.01 M | -12.69 M | — |
| EPS in Rs | -0.42 | -0.53 | 0.29 | 4.65 | -1.55 | -2.93 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 120.77 M | 128.94 M | 8.57 M | 63.57 M |
| Operating Profit | 35.86 M | -83.44 M | -276.01 M | -280.51 M |
| Net Profit | 32.69 M | -85.4 M | -276.13 M | -228.3 M |
| EPS in Rs | 4 | -10.44 | -33.76 | -27.92 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 20.23 M | 109.1 M | 165.5 M | 376.42 M |
| Total Liabilities | 58.74 M | 206.38 M | 264.74 M | 249.78 M |
| Equity | -38.5 M | -97.28 M | -99.23 M | 126.64 M |
| Current Assets | 12.21 M | 64.89 M | 101.87 M | 295.08 M |
| Current Liabilities | 14.92 M | 134.57 M | 142.23 M | 78.92 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -50.94 M | -68.72 M | -192.98 M | -270.43 M |
| Investing CF | 18.15 M | 8.62 M | 123.87 M | 202.96 M |
| Financing CF | 16.1 M | 59.28 M | 2.01 M | 53.08 M |
| Free CF | -50.94 M | -68.96 M | -194.2 M | -274.62 M |
| Capex | — | -0.25 M | -1.22 M | -4.19 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 1404.02% | -86.51% | — | — |
| Earnings Growth % | 69.07% | -20.95% | — | — |
| Profit Margin % | -66.23% | -3220.88% | -359.12% | — |
| Operating Margin % | -64.71% | -3219.48% | -441.25% | — |
| Gross Margin % | 83.71% | -3.65% | 100% | — |
| EBITDA Margin % | -58.75% | -3102.73% | -349.62% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2024-06-20 | 1:0.04 |